Subject:
Pharmacy
Credit units:
3
Offered:
Either Term 1 or Term 2
Weekly hours: 3 Lecture hours
College:
Pharmacy and Nutrition
Department: Pharm and Nutr (Dean's Office)
Description
This course will review and discuss: drugs recently approved by the regulatory bodies; drugs that have recently been unsuccessful in late stage clinical trials; new therapeutics in various phase clinical trials; clinical trials of natural products. Students will critically assess available data with a focus on new drugs and drugs in the pipeline. The goal will be to encourage students to be forward looking, self-directed learners for new therapeutics and develop a better understanding of the drug development and approval process.
Restriction(s): Completion of Year 1 of the Pharm.D. program
Prerequisite(s): PHAR 290.0
Note: Students with credit for PHAR 298 topic in "New and Emerging Therapeutics" will not receive credit for this course.
Upcoming class offerings
For full details about upcoming courses, refer to the class search tool or, if you are a current student, the registration channel in PAWS.
Syllabi
The syllabus is a public document that provides detail about a class, such as the schedule of activities, learning outcomes, and weighting of assignments and examinations.
Once an instructor has made their syllabus publicly available on USask’s Learning Management System, it will appear below. Please note that the examples provided below do not represent a complete set of current or previous syllabus material. Rather, they are presented solely for the purpose of indicating what may be required for a given class. Unless otherwise specifically stated on the content, the copyright for all materials in each course belongs to the instructor whose name is associated with that course. The syllabus is the intellectual property of instructors or the university.
For more information, visit the Academic Courses Policy , the Syllabus page for instructors , or for students your Academic Advising office.
Loading...